Carolina de Aguiar Ferreira , PhD

Assistant Professor

Radiology, Pharmacology & Toxicology

deaguia1@msu.edu

4113 iQ Building

Employment

Assistant Professor, Michigan State University, East Lansing, 2022 - Present

Publications

Preclinical Evaluation of Radium-223 and Immune Checkpoint Inhibitors Using an Immune-Competent Model of Prostate Cancer Bone Metastases Precision Oncology (2026)

Preclinical Evaluation of [ ¹⁷⁷ Lu]Lu-ART-101 for Radiopharmaceutical Therapy of Advanced Prostate Cancer Journal of Nuclear Medicine (2026)

Priming versus propagating: distinct immune effects of alpha- versus beta-particle emitting radiopharmaceuticals when combined with immune checkpoint inhibition in mice Nature Communications (2026)

Radionuclide-Dependent Stimulation of Antitumor Immunity in GD2-Targeted Radiopharmaceutical Therapy Combined with Immune Checkpoint Inhibitors Radiation (2025)

Enhanced Antitumor Efficacy of 225Ac-NM600 Compared to 177Lu-NM600 in Prostate Cancer Models International Journal of Radiation Oncology*Biology*Physics (2025)

Data from The Effects of Clinically Relevant Radionuclides on the Activation of an IFN1 Response Correlate with Radionuclide Half-life and Linear Energy Transfer and Influence Radiopharmaceutical Antitumor Efficacy (2025)

Figure S1 from The Effects of Clinically Relevant Radionuclides on the Activation of an IFN1 Response Correlate with Radionuclide Half-life and Linear Energy Transfer and Influence Radiopharmaceutical Antitumor Efficacy (2025)

Figure S2 from The Effects of Clinically Relevant Radionuclides on the Activation of an IFN1 Response Correlate with Radionuclide Half-life and Linear Energy Transfer and Influence Radiopharmaceutical Antitumor Efficacy (2025)

Figure S3 from The Effects of Clinically Relevant Radionuclides on the Activation of an IFN1 Response Correlate with Radionuclide Half-life and Linear Energy Transfer and Influence Radiopharmaceutical Antitumor Efficacy (2025)

Figure S4 from The Effects of Clinically Relevant Radionuclides on the Activation of an IFN1 Response Correlate with Radionuclide Half-life and Linear Energy Transfer and Influence Radiopharmaceutical Antitumor Efficacy (2025)

Fundings

manipulação e desenvolvimento de radiofármacos para uso em diagnóstico, por meio de imagens cintilográficas

materiais nanoestruturados multifuncionais

Noninvasive Imaging of Immune Activation Following PSMA-Targeted Radiopharmaceutical Therapy in Prostate Cancer

In the News

From top: Dr. Carolina de Aguiar Ferreira; Dr. Jinda Fan: and Dr. Kurt Zinn.

Trio of researchers bring their expertise in radiopharmaceutical drug development to the PhmTox department

Dr. Kurt Zinn, Dr. Jinda Fan and Dr. Carolina de Aguiar Ferreira have years of experience in the field and are anxious to merge their backgrounds in Drug Discovery research and more . "This is a really good fit," Dr. Zinn said.